SHP2 contributes significantly to tumorigenesis in several cancers, including breast cancer, where it participates in cancer cell initiation, invasion, metastasis, and drug resistance, making it an attractive therapeutic target (Song et al., 2021). The gene discussed is PTPN11; the disease is cancer.